Squawk on the Street CNBC Investing Club: Cramer’s Morning Take on Eli Lilly 2/4/26
4 snips
Feb 4, 2026 Discussion of how one pharma company leads in clinical trials and upcoming studies for alcohol and tobacco. Conversation about market implications of a new oral GLP-1 pill and how pill convenience could sway patient choice. Comparison of competitive guidance and revenue moves following recent earnings news.
AI Snips
Chapters
Transcript
Episode notes
Lilly's Trial Lead Widens The Gap
- Jim Cramer says Eli Lilly is far ahead of Novo Nordisk in clinical trials, creating a widening gulf between the companies.
- He points to Lilly's alcohol, tobacco, and weight-related arthritis trials as signs of durable advantage.
Novo's Growth Comes From New Patients
- Carl Quintanilla highlights Novo Nordisk's strong quarter and bullish guidance driven by volume.
- He notes category expansion from new oral GLP-1 pills bringing new patients, not just switching users.
Real-World Limits Can Change Market Share
- Lilly's upcoming oral competitors will face real limitations like fasting requirements that affect real-world use.
- Cramer argues these differences will influence market share even with similar clinical results.